Agenus Inc logo

Agenus Inc

1
NAS:AGEN (USA)  
$ 0.56 +0.02 (+3.73%) 11:09 PM EST
At Loss
Market Cap:
$ 233.09M
Enterprise V:
$ 227.03M
Volume:
3.56M
Avg Vol (2M):
11.24M
Also Trade In:
Volume:
3.56M
At Loss
Avg Vol (2M):
11.24M

Business Description

Description
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).
Name Current Vs Industry Vs History
Cash-To-Debt 0.98
Equity-to-Asset -0.51
Debt-to-Equity -0.49
Debt-to-EBITDA -0.54
Piotroski F-Score 3/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score -10.15
Distress
Grey
Safe
Beneish M-Score 2.7
Manipulator
Not Manipulator
WACC vs ROIC
WACC
ROIC
Name Current Vs Industry Vs History
5-Day RSI 44.03
9-Day RSI 39.52
14-Day RSI 40.69
6-1 Month Momentum % -33.52
12-1 Month Momentum % -49.19

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 0.44
Quick Ratio 0.44
Cash Ratio 0.3
Days Sales Outstanding 15.11
Days Payable 74.48

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -26.2
Shareholder Yield % -59.25

Financials (Next Earnings Date:2024-05-09 Est.)

AGEN's 30-Y Financials
Income Statement Breakdown
No Enough Data
Balance Sheet Breakdown
No Enough Data
Cashflow Statement Breakdown
No Enough Data

Historical Operating Revenue by Business Segment

Historical Operating Revenue by Geographic Region

5-Step DuPont Analysis as of
No Enough Data

Guru Trades

See Details
To

Insider Trades

See Details
To

Gurus Latest Trades with NAS:AGEN

No Available Data

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To

Performance

Dividend
Log
Bar
To

Annualized Return %  

Symbol
1 Week
1 Month
3 Months
6 Months
YTD
1 Year
3 Years
5 Years
10 Years

Total Annual Return %  

Symbol
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015

Agenus Inc Executives

Details

Valuation Chart

Year:

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil $) 156.313
EPS (TTM) ($) -0.7
Beta 1.29
Volatility % 42.53
14-Day RSI 40.69
14-Day ATR ($) 0.059679
20-Day SMA ($) 0.61515
12-1 Month Momentum % -49.19
52-Week Range ($) 0.485 - 2.13
Shares Outstanding (Mil) 418.92

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 3
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Agenus Inc Filings

Filing Date Document Date Form
No Filing Data

Agenus Inc Stock Events

Financials Calendars
Event Date Price($)
No Event Data

Agenus Inc Frequently Asked Questions

What is Agenus Inc(AGEN)'s stock price today?
The current price of AGEN is $0.56. The 52 week high of AGEN is $2.13 and 52 week low is $0.49.
When is next earnings date of Agenus Inc(AGEN)?
The next earnings date of Agenus Inc(AGEN) is 2024-05-09 Est..
Does Agenus Inc(AGEN) pay dividends? If so, how much?
Agenus Inc(AGEN) does not pay dividend.

Press Release

Subject Date
No Press Release

Headlines

See More
  • 1
No news.
  • 1